Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma.
M Cheminant, J Bruneau, O Kosmider… - British journal of …, 2015 - search.ebscohost.com
M Cheminant, J Bruneau, O Kosmider, F Lefrere, R Delarue, P Gaulard, I Radford…
British journal of haematology, 2015•search.ebscohost.comThe article presents a case study of a woman born in 1933 who was diagnosed with chronic
myelomonocytic leukaemia (CMML) in 2003. The patient, over a period of 10 years,
developed fatigue and lymphadenopathy with high level of lactate dehydrogenase. The
article discusses efficiency of Five-Azacytidine therapeutic agent in angioimmunoblastic T
cell lymphoma due to mutations in genes involved in DNA methylation, such as TET2.
myelomonocytic leukaemia (CMML) in 2003. The patient, over a period of 10 years,
developed fatigue and lymphadenopathy with high level of lactate dehydrogenase. The
article discusses efficiency of Five-Azacytidine therapeutic agent in angioimmunoblastic T
cell lymphoma due to mutations in genes involved in DNA methylation, such as TET2.
Abstract
The article presents a case study of a woman born in 1933 who was diagnosed with chronic myelomonocytic leukaemia (CMML) in 2003. The patient, over a period of 10 years, developed fatigue and lymphadenopathy with high level of lactate dehydrogenase. The article discusses efficiency of Five-Azacytidine therapeutic agent in angioimmunoblastic T cell lymphoma due to mutations in genes involved in DNA methylation, such as TET2.
search.ebscohost.com
